PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.

Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.

Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.

Steven B. Heymsfield, MD, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.

Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.